New Antifungals for Vulvovaginal Candidiasis: What Is Their Role?
review · Level V
Where this comes from
- Record sourced from PubMed, PMID 36610791.
- Also identified by DOI 10.1093/cid/ciad002.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
New antifungals, ibrexafungerp and oteseconazole, are now available for treatment of vulvovaginal candidiasis. Both have novel antimicrobial and pharmacokinetic properties and advantages over fluconazole, although comparative trials have involved only placebo. In the absence of allergy, intolerance, and resistance, it is unclear whether these antifungals will replace fluconazole.
Medical subject headings
- Antifungal Agents
- Candidiasis, Vulvovaginal